WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 464342

CAS#: 39219-28-8

Description: Promestriene is a synthetic estrogen and derivative of estradiol. Topical application of a gel containing promestriene (1%) reduces vaginal atrophy and decreases in endometrial and myometrial wall thickness in ovariectomized rats. Formulations containing promestriene have been used in the treatment of vaginal atrophy.

Chemical Structure

CAS# 39219-28-8

Theoretical Analysis

MedKoo Cat#: 464342
Name: Promestriene
CAS#: 39219-28-8
Chemical Formula: C22H32O2
Exact Mass: 328.24
Molecular Weight: 328.496
Elemental Analysis: C, 80.44; H, 9.82; O, 9.74

Price and Availability

Size Price Availability Quantity
10mg USD 400 2 Weeks
25mg USD 700 2 Weeks
50mg USD 1090 2 Weeks
100mg USD -2 2 Weeks
200mg USD -2 2 Weeks
500mg USD -2 2 Weeks
1g USD -2 2 Weeks
2g USD -2 2 Weeks
5mg USD 240 2 Weeks
Bulk inquiry

Synonym: Promestriene;

IUPAC/Chemical Name: (8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene


InChi Code: InChI=1S/C22H32O2/c1-4-13-24-16-6-8-17-15(14-16)5-7-19-18(17)11-12-22(2)20(19)9-10-21(22)23-3/h6,8,14,18-21H,4-5,7,9-13H2,1-3H3/t18-,19-,20+,21+,22+/m1/s1

SMILES Code: C[C@]12[C@]([H])([C@]3([C@@]([H])(C4=CC=C(C=C4CC3)OCCC)CC2)[H])CC[C@@H]1OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Product Data:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMF 15.0 0.00
DMSO 5.0 0.00

Preparing Stock Solutions

The following data is based on the product molecular weight 328.496000000000000000000000000000 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: de Albuquerque Coelho SC, Giraldo PC, Brito LGO, Juliato CRT. ESTROgen use for complications in women treating pelvic organ prolapse with vaginal PESSaries (ESTRO-PESS)-a randomized clinical trial. Int Urogynecol J. 2021 Jan 26. doi: 10.1007/s00192-020-04654-1. Epub ahead of print. PMID: 33501563. 2: Gorduza D, Plotton I, Remontet L, Gay CL, El Jani M, Cheikhelard A, Blanc T, El Ghoneimi A, Leclair MD, Roy P, Pirot F, Mimouni Y, Gaillard S, Chatelain P, Morel Y, Kassai B, Mouriquand P. Preoperative Topical Estrogen Treatment vs Placebo in 244 Children With Midshaft and Posterior Hypospadias. J Clin Endocrinol Metab. 2020 Jul 1;105(7):dgaa231. doi: 10.1210/clinem/dgaa231. PMID: 32386308. 3: Aguiar LB, Politano CA, Costa-Paiva L, Juliato CRT. Efficacy of Fractional CO2 Laser, Promestriene, and Vaginal Lubricant in the Treatment of Urinary Symptoms in Postmenopausal Women: A Randomized Clinical Trial. Lasers Surg Med. 2020 Oct;52(8):713-720. doi: 10.1002/lsm.23220. Epub 2020 Jan 28. PMID: 31990089. 4: Ramalho NM, Carneiro VCG. To the Editor. Menopause. 2020 Jan;27(1):119. doi: 10.1097/GME.0000000000001464. PMID: 31834158. 5: Costa-Paiva L, Politano CA, Aguiar LB, Baccaro LF. In Reply. Menopause. 2020 Jan;27(1):119-120. doi: 10.1097/GME.0000000000001466. PMID: 31834157. 6: Politano CA, Costa-Paiva L, Aguiar LB, Machado HC, Baccaro LF. Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause. 2019 Aug;26(8):833-840. doi: 10.1097/GME.0000000000001333. PMID: 31246661. 7: Hickey M, Richards AM. Vaginal laser treatment-first, do no harm. Menopause. 2019 Aug;26(8):814-815. doi: 10.1097/GME.0000000000001376. PMID: 31211709. 8: Chen X, Guo H. Comparison of Chlorquinaldol-Promestriene Vaginal Tablets and Opin Suppositories Effect on Inflammatory Factors and Immune Function in Chronic HPV Cervicitis. J Coll Physicians Surg Pak. 2019 Feb;29(2):115-118. doi: 10.29271/jcpsp.2019.02.115. PMID: 30700347. 9: Oyarzún MFG, Castelo-Branco C. Local hormone therapy for genitourinary syndrome of menopause in breast cancer patients: is it safe? Gynecol Endocrinol. 2017 Jun;33(6):418-420. doi: 10.1080/09513590.2017.1290076. Epub 2017 Feb 21. PMID: 28277141. 10: Sun Z, Zhu L, Xu T, Shi X, Lang J. Effects of preoperative vaginal estrogen therapy for the incidence of mesh complication after pelvic organ prolapse surgery in postmenopausal women: is it helpful or a myth? A 1-year randomized controlled trial. Menopause. 2016 Jul;23(7):740-8. doi: 10.1097/GME.0000000000000614. PMID: 27163518. 11: Jiang F, Zhu L, Xu T, Gong MY, Huang YL, Li HF, Wang JJ, Tong XW, Cheng XX, Bai WP, Li X, Xu XX, Xu HC. Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women--a multicenter, randomized, open- label, controlled comparison study. Menopause. 2016 Apr;23(4):451-7. doi: 10.1097/GME.0000000000000574. PMID: 26757270. 12: Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P, Berretta M. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients? Anticancer Drugs. 2013 Nov;24(10):989-98. doi: 10.1097/CAD.0b013e328365288e. PMID: 24080714. 13: Salmon D, Kassai B, Roussel L, Mouriquand P, Gérard C, Gorduza DB, Serre C, Falson F, Pivot C, Pirot F. Ex vivo absorption of promestriene from oil-in-water emulsion into infant foreskin. Int J Pharm. 2013 Nov 1;456(1):121-4. doi: 10.1016/j.ijpharm.2013.08.005. Epub 2013 Aug 19. PMID: 23968783. 14: López-Belmonte J, Nieto C, Estevez J, Delgado JL, del Prado JM. Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations. Maturitas. 2012 Aug;72(4):353-8. doi: 10.1016/j.maturitas.2012.05.007. Epub 2012 Jun 9. Erratum in: Maturitas. 2013 Apr;74(4):393. PMID: 22683083. 15: Del Pup L. Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients. Gynecol Endocrinol. 2012 Sep;28(9):740-5. doi: 10.3109/09513590.2011.652717. Epub 2012 Mar 12. PMID: 22409649. 16: Del Pup L, Postruznik D, Corona G. Effect of one-month treatment with vaginal promestriene on serum estrone sulfate levels in cancer patients: a pilot study. Maturitas. 2012 May;72(1):93-4. doi: 10.1016/j.maturitas.2012.01.017. Epub 2012 Feb 18. PMID: 22349253. 17: Santos I, Clissold S. Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy. Gynecol Endocrinol. 2010 Sep;26(9):644-51. doi: 10.3109/09513591003767948. PMID: 20374067. 18: Sun AJ, Lin SQ, Jing LH, Wang ZY, Ye JL, Zhang Y. [Safety of promestriene capsule used in postmenopausal atrophic vaginitis]. Zhonghua Fu Chan Ke Za Zhi. 2009 Aug;44(8):593-6. Chinese. PMID: 20003787. 19: Kobata SA, Girão MJ, Baracat EC, Kajikawa M, Di Bella V Jr, Sartori MG, Jármy-Di Bella ZI. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis. Maturitas. 2008 Nov 20;61(3):243-7. doi: 10.1016/j.maturitas.2008.07.015. Epub 2008 Oct 9. PMID: 18845407. 20: Piccoli R, Mandato VD, Lavitola G, Acunzo G, Bifulco G, Tommaselli GA, Attianese W, Nappi C. Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: implications for management. Eur J Obstet Gynecol Reprod Biol. 2008 Oct;140(2):269-74. doi: 10.1016/j.ejogrb.2008.05.007. Epub 2008 Jul 7. PMID: 18603346.